Púdar Aigéad Tranexamic

Buntáistí Príomhúla Púdar Aigéad Tranexamic

• Meicníocht Spriocdhírithe Beacht By competitively inhibiting plasminogen activation, it stabilizes blood clots, achieving highly effective hemostasis without directly activating the coagulation system, thereby reducing the risk of systemic thrombosis.
• Formhuiniú Fianaise-Bhunaithe agus Údarásach Included in the World Health Organization’s List of Essential Medicines and highly recommended in clinical guidelines across multiple fields, including orthopedics, obstetrics and gynecology, and trauma surgery, it effectively reduces the need for blood transfusions during surgery and lowers trauma mortality rates.
• Sochair Ilfheidhmeacha Leathnaithe It combines skin-lightening properties for treating melasma with anti-inflammatory effects, offers good overall safety, and is rarely associated with serious adverse reactions.

Éifeachtaí Púdar Aigéad Tranexamic

• Hemostasis an-éifeachtach By stabilizing fibrin clots through its antifibrinolytic action, it significantly reduces perioperative blood loss and lowers the need for allogeneic blood transfusions; it can significantly improve the survival rate of patients with severe hemorrhage.
• Bainistiú Coinníollacha Sonracha An cógas déileálann menorrhagia, severe epistaxis, and hemoptysis; it also cosc fuiliú iar-eastósctha in othair hemophilia agus fuiliú tánaisteach tar éis hemorrhage trámach sa tseomra roimhe
• Éadromú Craiceann agus Frith-athlasadh By inhibiting melanocyte activation signals, it improves melasma and post-inflammatory hyperpigmentation; simultaneously, by reducing vascular permeability, it provides adjunctive treatment for hereditary angioedema, urticaria, and similar conditions.

Heavy Metals (Chemical Control)

Tástálacha Micribhitheolaíochta